Anticancer drugs could make immunotherapies more effective
December 10, 2024
December 10, 2024
ITHACA, New York, Dec. 10 -- Cornell University issued the following news:
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
The inhibitors target the EZH2 enzyme, whose activity in tumor cells is now recognized as a significant factor in many cancers. The study, published Dec. 5 in Cancer Cell, found that EZH2 i . . .
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
The inhibitors target the EZH2 enzyme, whose activity in tumor cells is now recognized as a significant factor in many cancers. The study, published Dec. 5 in Cancer Cell, found that EZH2 i . . .